Insider Buying News: Cytori Therapeutics Inc (CYTX), Celldex Therapeutics, Inc. (CLDX), Nuance Communications Inc. (NUAN), Amgen, Inc. (AMGN)


Recently, various executives have taken part in insider buying activity for the stocks of Cytori Therapeutics Inc (NASDAQ:CYTX), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Nuance Communications Inc. (NASDAQ:NUAN), and Amgen, Inc. (NASDAQ:AMGN).

Cytori Therapeutics Inc

President and CEO Marc Hedrick bought 10,000 shares worth $3,899 at an average price of $0.39, as reported in the SEC filing yesterday. Following the insider-buying transaction, his stake in Cytori Therapeutics has now grown to $525,711 shares with a value of $205,027.

Click Here to see the performance of Cytori Therapeutics insiders.

Celldex Therapeutics, Inc.

Celldex has been backed by positive insider activity as the company’s Director, Larry Ellberger, acquired a total of 5,000 shares yesterday, taking his total stake to 48,500 shares. The stock purchase was worth $75,000, at an average price of $15.00 per share.

Click Here to see the performance of Celldex Therapeutics insiders.

Nuance Communications Inc.

Director Robert Frankenberg sold 4,162 Nuance Communications shares, valued $32,463, in multiple transactions dated August 18. After completion of the transactions, Frankenberg owns $105,000 shares worth $1,859,550.

Click Here to see the performance of Nuance Communications insiders.

Amgen, Inc.

Director Fred Hassan acquired $3,010 Amgen shares (worth $501,545) at a price of $166.63, in two transactions dated August 19. The director now has a total stake of 3,582 shares worth $569,431. According to TipRanks.com, which measures corporate insiders’ success based on their transactions, Fred Hassan has an average return of 2.9% and a 40% success rate. Hassan is ranked #12048 out of 33597 corporate insiders.

Click Here to see the performance of Amgen insiders.